Biologic Predictors of Leiomyoma Treatment Outcomes
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cervical Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | August 2009 |
| End Date: | December 2016 |
The purpose of this study is to search for the hereditary (genetic) causes of uterine
fibroids. Some women with uterine fibroids may have one or more genes that make them more
likely to develop uterine fibroids. We are trying to identify these genes to better
understand how and why uterine fibroids develop and to design better treatment options for
women with uterine fibroids. This information may also help us to understand and treat other
problems that may be caused by these genes.
fibroids. Some women with uterine fibroids may have one or more genes that make them more
likely to develop uterine fibroids. We are trying to identify these genes to better
understand how and why uterine fibroids develop and to design better treatment options for
women with uterine fibroids. This information may also help us to understand and treat other
problems that may be caused by these genes.
There is little information to predict outcomes of leiomyoma therapies. It is clear that
both environmental exposures and genetic predisposition influence disease manifestations.
Our work has identified a new area of genetic linkage for leiomyomas from a genome wide
scan. We therefore propose to prospectively collect biologic samples that will allow us to
analyze gene/environment interactions of women enrolled in leiomyoma clinical trials or
undergoing leiomyoma clinical treatments using the same methodology used previously.
Specifically we will collect serum aliquots, genomic DNA and information using a genetic
epidemiology questionnaire. In the short term we will also be able to use prospectively
obtained information on epidemiologic and anthropomorphic data to characterize women
undergoing treatment.
both environmental exposures and genetic predisposition influence disease manifestations.
Our work has identified a new area of genetic linkage for leiomyomas from a genome wide
scan. We therefore propose to prospectively collect biologic samples that will allow us to
analyze gene/environment interactions of women enrolled in leiomyoma clinical trials or
undergoing leiomyoma clinical treatments using the same methodology used previously.
Specifically we will collect serum aliquots, genomic DNA and information using a genetic
epidemiology questionnaire. In the short term we will also be able to use prospectively
obtained information on epidemiologic and anthropomorphic data to characterize women
undergoing treatment.
Inclusion Criteria:
1. Able and willing to give consent
2. Age 18 or older
3. Presence of known uterine leiomyoma
Exclusion Criteria:
1. Suspected malignancy
We found this trial at
1
site
Click here to add this to my saved trials
